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Summary 
Downregulation of major histocompatibility complex class I expression is causally related  to 
high malignancy and low immunogenicity of certain murine tumors. In this study, we have 
analyzed  the roles of the nuclear factors KBF1/p50 and p65 in regulation of class I expression 
in high and low metastatic tumor cells. Low class I-expressing cells show at higher levels of 
KBF1/p50 and NF-xB (p50/p65) binding activity than high class I-expressing cells. However, 
an excess of KBF1 over NF-~B is observed in low expressing cells, while an excess of NF-xB 
over KBF1 is observed in high expressing cells. Stable transfection of a p65 expression vector 
into low class I-expressing cells activated  H-2 transcription and cell surface expression,  while 
stable  transfection  of pS0  expression  vector  into  high  expressing cells  suppressed  H-2K  b 
transcription and cell surface expression.  Our studies suggest that KBF1  has the potential of 
downregulating class I gene expression, whereas dimers containing the p65 subunit are activators 
of class I gene expression. 
C 
lass I molecules of the MHC present peptide fragments 
from intracellularly processed antigens to CTL (1, 2). 
Reduced levels of expression of H-2 class I proteins were ob- 
served in spontaneous, chemically induced, and virally trans- 
formed murine tumors (3-8), human small cell carcinomas 
(9), neuroblastomas (10), eccrine pr0tocarcinomas (11), cer- 
vical  carcinomas (12), and Burkitt's lymphoma lines (13). 
Moreover, examination of 44 primary tumors and autologous 
metastases  showed significant  downregnlation of class I in 
metastases (14). In many of the experimental tumor systems, 
the lack of H-2 expression determined reduced immunoge- 
nicity and high tumorigenicity. 
The Lewis lung carcinoma (3LL) tumor that originated 
spontaneously in a C57B1, H-2  b mouse almost lacks cell sur- 
face  expression of H-2K  b antigen  (3).  Screening a  large 
number of newly generated single cell clones of 3LL showed 
that the higher the metastatic phenotype of a clone, the lower 
the expression of H-2K  b glycoprotein; H-2D  b, on the other 
hand, is expressed to some extent on most clones (15). The 
low metastatic H-2Kb-positive  clones  were  shown to  be 
significantly more immunogenic both in syngeneic and in 
allogeneic hosts,  compared with  high  metastatic  H-2K- 
negative cells (15). It therefore appeared  that putative pep- 
tides derived from tumor antigens could be recognized by 
CTL only in association  with H-2K  s gene products, while 
H-2D  b molecules do not serve as a restriction element for 
antitumor CTL (16). In vitro treatment by IFN-3~ transiently 
activated the expression  of H-2K  b gene in the metastatic 
clones (17). When cells treated for 5 d with IFN-7 were in- 
jected intravenously into mice, a significant decrease in their 
metastatic competence was observed (17-19).  Since IFN-3, 
is known to affect many different functions of the cells, we 
tested whether the reduction of metastatic competence by 
IFN-7 can be attributed directly to the induction of H-2K  b 
expression, by introducing H-2K  b gene into cells of a highly 
metastatic,  Kb-negative  clone,  called  D122.  We  demon- 
strated that cells of a highly metastatic done, transfected with 
H-2K  b gene, reverted to low or nonmetastatic phenotypes. 
This was correlated with the acquisition of H-2K-restricted 
immunogenic properties (20, 21). Low levels of class I cell 
surface expression in most tested tumors, of human or mu- 
fine origin, are the result of low mKNA levels, and only 
rarely are defects in protein transport, peptide processing, or 
MHC-peptide assembly described (22, 23). The unique model 
of the 3LL carcinoma enables a direct analysis of the tran- 
scriptional mechanism responsible for the differential  class 
I expression  in high and low expressing clones. 
Analysis of the mouse MHC class I promoter has revealed 
several regions important for the expression and regulation 
of these genes through specific binding of proteins (24-34). 
The promoter-enhancer region of class I genes includes two 
main enhancer sequences, A and B. Enhancer A overlaps with 
the IFN-responsive sequence (IRS) (-163,  -137). Both en- 
hancers are conserved within the promoter of several genes 
coding for classical transplantation antigens. In most cells or 
tissues of human, rat, or mouse origin, a nuclear factor called 
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dromes, within the A enhancer (25, 35, 36). This constitu- 
tive nuclear factor also binds to a similar sequence, within 
the promoter of the mouse ~z-m gene (35). KBF1 was thus 
expected to play a role in the coordinate up regulation  of 
class  I  and B2-m gene expression (35). 
Another factor binding to the palindrome sites in class I 
gene enhancers and the ~2-m promoter is NF-gB (28, 37). 
This inducible factor is thought to displace the constitutive 
KBF1 upon treatment of cells with TNF and phorbol ester, 
thereby replacing a weakly trans-activating factor by a strong 
activator  (36).  NF-KB is composed of two DNA binding 
subunits called pS0 and p65 (38-40). A third subunit, called 
IgB, serves to inhibit the DNA binding and nuclear translo- 
cation of the pS0-p65 heterodimer (41).  The release of IgB 
in response to a multitude of external stimuli provides the 
molecular basis for the inducible activation of NF-~B (reviewed 
in reference 42). p50 and p65 share sequence homology and 
are members of a novel class of transcription factors also in- 
cluding the Rel protooncogene (for review, see reference 43). 
KBF1 is, by all criteria tested, identical to a homodimer of 
the pS0 subunit of NF-gB (44-46), p50 homodimers escape 
inducible control because they cannot detectably interact with 
purified IKB proteins, unlike dimers containing p65. A unique 
feature of pS0/KBF1  is its  synthesis of a large non-DNA 
binding precursor molecule, p105, with endogenous IKB ac- 
tivity in its COOH-terminal  portion  (47-49). 
KBF1 (p50 NF-gB homodimer) is present in most differen- 
tiated cells where MHC class I antigens are expressed. How- 
ever, its binding activity is absent in undifferentiated  embryonal 
carcinoma (EC) cells,  where class I  and B2-m genes are si- 
lent.  It is induced when the cells are triggered to differen- 
tiate (28),  and the appearance of KBF1 binding  activity in 
EC cells parallels  the onset of H-2 class I and B2-m gene ex- 
pression (mRNA and proteins). KBFl-like binding activity 
is undetectable in brain nuclear extracts, which correlates with 
the lack of H-2 class I antigens in this organ (50). Its absence 
from fetal mouse liver nuclear extracts is however in contrast 
to class I expression from midsomite stage of gestation on- 
wards (50). In stage-specific T  cell lines,  the level of class I 
transcription  has been shown to correlate with the amount 
of KBFl-like binding activity (51). Another factor, H-2 tran- 
scription factor (H2TF1), binds also to enhancer A at exactly 
the same nucleotide residues as KBF1 (52), but its relation- 
ship to KBF1 is unclear at present. Recent reports show that 
homodimers of pS0 (KBF1) lack significant trans-activating 
potential in transient transfection assays but rather have the 
potential  of  downregulating  KB-specific  gene  expression 
(53-55).  In contrast,  in vitro transcription  studies showed 
that p50 dimers act as activators of gene transcription (56, 57). 
These conflicting observations prompted us to test whether 
stable expression of KBF1 in 3LL carcinoma cell lines posi- 
tively or negatively influences class I gene expression.  Our 
data suggest that KBFt is a negative regulator of class I ex- 
pression, whereas the p65 subunit of NF-KB is a positive regu- 
lator. These results suggest that the balance between the two 
NF-KB subunits is crucial for the level of class I expression. 
Materials  and Methods 
Tumor Cells.  Tumor cells were maintained in DME, 10% FCS, 
and supplements described elsewhere (4). The Lewis lung carci- 
nomas (3LL) is a malignant tumor that originated spontaneously 
in C57BL/6  (H-2  b) mice (4).  A9 and D122 are low and high 
metastatic clones, respectively,  cloned from the 3LL carcinoma cells 
by limiting  dilution  (4). 
Gene Expression.  RNAs were prepared from 1-3  x  10  s cells, 
propagated in tissue culture, by the method of Chirgwin et al. (58). 
Northern blots were prepared from formaldehyde-containing agarose 
gels loaded with 40/~g total RNA per lane as described (21) and 
assayed by hybridization  to  32p-labeled probes.  The  following 
probes were used: for the H-2K  b probe, the H-2KLspecific 30-mer 
oIigonucleotide,  which  codes for  amino  acids 290-299  of the 
H-2K  b protein;  for the H-2D  b probe, the H-2Db-specific 30-mer 
oligonucleotide,  which  codes for amino  acids 293-302  of the 
H-2D  b protein;  for the p50 probe, a 1.5-kbp insert of pBLS0 (a 
gift of S. Ruben, Roche Institute,  NJ) (59); for the p65 probe, 
a 2.0-kbp insert ofpBL65 (a gift orS. Ruben) (59); for the/3-actin 
probe, a 4.3-kbp insert of pAC18.1 (a gift ofU. Nudel; Weizmann 
Institute, Rehovot, Israel) (60). Hybridizations were performed in 
50% formamide at 42~  Blots were washed in 0.1x  SSC, 0.1% 
SDS at 60~  Blots hybridized  to oligonudeotide probes were 
washed in 0.5 x  SSC, 0.1%  SDS at 50~ 
Plasmids, Constructs, Antibodies, and Proteins.  Plasmids  RcCMV- 
pS01~ and RcCMV-p651-s5~  were described previously (53). PUC- 
365-CAT was prepared by cloning  of a BamHI-Xbal restriction 
fragment  from pH-2-CAT  (a gift of A. Israel, Pasteur Institute, 
Paris) (61) into a Puc19 vector. PUC-142-CAT and PUC-190-CAT 
were subcloned from p138H-2K CAT and p190H-2K CAT (a gift 
from A. Baldwin,  Massachusetts Institute of Technology, Cam- 
bridge, MA) (52), respectively, into a Puc19 vector (52). p38-H- 
2K-CAT (a gift from A. Baldwin) and the B galactosidase-con- 
taining expression vector PCHl10 (Pharmacia Fine Chemicals, Pis- 
cataway, NJ). Recombinant  p50 and p65 were prepared by the 
MAXIBAC baculovirus expression system (a gift olD. Baltimore, 
The Rockefeller  University, New York) (56), and antibodies to KBF1 
a2 and a3 were a gift of A. Israel (44). IgB recombinant MAD-3 
was expressed in bacteria and purified as described (61a). Antibodies 
to c-tel (a gift of I. Verma, The Salk Institute,  San Diego, CA), 
and antibodies to v-tel (a gift of M. Hannink,  University of Mis- 
souri,  Columbia,  MO) were used. 
Preparation of Stable Transfectants.  Transfections of H-2K  b, 2.9- 
K  b,  4.1-K  b,  and  RcCMV-p65  expression vectors into  the high 
metastatic clone D122 (3LL) and transfection of RcCMV-pS0 into 
the low metastatic done A9 (3LL) were performed by the calcium 
phosphate technique, in cotransfection with a 1:9 ratio of PSV2- 
neomycine resistance gene (PSV2neomycin) (21). Control transfec- 
tion was done with PSV2neo alone. To increase the efficiency of 
transfection,  a 3-min  treatment  with DME,  15%  glycerol was 
preformed  after  incubation  with  DNA  precipitates.  Colonies 
growing in 400/~g/ml (19122 cells) and 800/~g/ml (A9 cells) G418 
(GIBCO BRL, Gaithersburg,  MD) 4 wk after transfection were 
expanded and analyzed for expression of the inserted genes. Con- 
trol transfectants carrying pSV2neo show hybridization  patterns, 
and MHC class I expression equal to parental cells. Positive clones 
were checked for plasmid DNA integration  by Southern  blots. 
Cell Surface and Cellular H-2 Proteins.  To determine cell surface 
H-2  expression,  protein  A-purified  mAbs  20-8-4  (c~K  b)  and 
28-14-8 (ctD  b) (62) were iodinated by chloramine T. 500 ng of 
labeled antibody was mixed with 5  x  105 freshly trypsinized cells 
in 0.1 ml PBS in BSA-coated  tubes. Triplicate samples were incubated 
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sodium azide, samples were monitored in a gamma scintillation 
counter. Immunoprecipitation  of class I proteins from [35S]methio- 
nine-labeled cells were described previously (4). 
Transient ExFression Assays.  For transient assays, 106 cells were 
plated in 10-cm dishes, 24 h before DNA transfection. Cells were 
incubated for 12 h with calcium phosphate-precipitated plasmid 
DNAs (20/~g of the CAT derivative  plus 4/~g of pCH110). Then, 
after a 3-min glycerol (15%, 37~  shock, the cells were rinsed 
once, reefed with fresh medium, and 24-48 h later the cells were 
processed for enzymatic assays. CAT activity, using 30/zg of total 
cell extract protein, was determined as described by Schiile et al. 
(63) and 3-galactosidase activity was determined as described by 
Nielson et al. (64). Experiments were repeated at least three times. 
Activity of CAT was normalized to activity of B-galactosidase to 
correct for difference in transfection efhciency. 
Gel Retardation Assay.  Nuclear  extracts were prepared from 107 
cells and used in gel retardation assays as described by Schreiber 
et al. (65). Protein concentration was determined using the Brad- 
ford method and ranged from 4 to 7 mg/ml. A synthetic double- 
stranded 52-bp oligodeoxynucleotide  containing the entire enhancer 
A (-205 to -154) of the H-2K  b promoter, a 66-bp oligonucleo- 
tide containing the entire enhancer  B (-123 to -58) of the H-2K  b 
promoter, a 13-bp oligonucleotide containing the NF-rB/KBF1 
binding domain, and a 375-bp fragment containing the entire en- 
hancer A and B (XbaI-HindlII-restricted  fragment from pH-2-CAT) 
were used as probes. The nonlabeled competitor oligonucleotides 
used in the binding assay  were: AP1 (-203 to -190), APIAX (-205 
to  -184),  AP2 (-184 to  -172), AP2X (-188 to  -169), class I 
regulatory element (CRE)  (-172  to  -160),  CREX  (-175  to 
-154),  and AP1B (-106 to  -92). 
DNA-protein  binding was conducted in 20-/zl volumes. Nu- 
clear extracts (3-5 #g) were incubated with 3/zg of poly(dI:dC) 
(Pharmacia Fine Chemicals) for 15 rain at room temperature. Ap- 
proximately 0.1  pmol of 32P-labeled DNA  (,,~10,000 cpm) was 
added to the preincubated nuclear extracts. Unlabeled competitor 
DNAs were added to the binding reactions 2 rain before the la- 
beled oligomer. Rabbit anti-pS0 antiserum was added to the nu- 
clear extracts for 15 rain at 4~  before 32P-labeled DNA addition. 
No disruption of the nucleoprotein complex binding was observed 
when a control antisera was added to the extract. DNA-protein 
complexes were resolved  on 4% polyacrylamide  gel (acrylamide/bis- 
acrylamide, 39:1) in 0.4x  TBE (lx  TBE is 50 mM Tris-borate 
[pH 8] 1 mM EDTA). The gels were dried and autoradiographed 
with intensifying screens at  -70~ 
Construction of Genomic 1)122 DNA Library.  10-20-kbp frag- 
ments  of D122 genomic DNA  were ligated  to predigested X 
dash/EcoRI arms (Stratagene,  LaJolla, CA). The library was plated 
out at a density of 20,000 plaques per plate (20 plates). Replica 
filters were prepared from each plate. After denaturation and neu- 
tralization, the filters were hybridized with an H-2K  b oligomer 
probe. Two specific  clones  were isolated. EcoRI-digested  fragments 
from the two clones, containing the whole H-2K  b gene, were sub- 
cloned into Bluescript plasmid for further analysis. 
cellular protein, and mRNA levels of the K b gene.  Fig.  1 
shows high levels of transcript, total cellular heavy chain, and 
cell surface antigen on A9 as compared with D122.  H-2D  b 
cell surface expression is readily detectable on D122 cells and 
it is approximately threefold lower on D122  cells as com- 
pared with A9 cells (see Figs.  6 D  and 7 C) (21). We have 
shown before that transfection of D122 cells with a plasmid 
containing the K b gene cloned from a normal genomic li- 
brary and driven by an autologous promoter yielded K b- 
positive clones, provided that a high copy number of the gene 
was inserted (21). To test whether the D122 endogenous K b 
gene can be expressed  under similar conditions, we cloned 
the gene from a D122 genomic library (Xdash). Restriction 
analysis with a variety of restriction enzymes indicated that 
no gross mutations, deletions, or rearrangements occurred 
in the K b genomic clones. Two genomic clones,  2.9-K  b and 
4.1-K  b, 10.5 kbp in length, which include the entire K b pro- 
moter, were subcloned into Bluescript and were used for trans- 
fection into D122  cells.  The H-2K  b clone derived from a 
normal library was transfected in parallel.  Fig. 2 shows that 
either of the two D122-derived plasmids or the normal K b 
were all expressed in D122 cells at similar levels. No significant 
changes in D b expression  were observed as compared to pa- 
rental cells. DNA analysis indicated that multiple copies  of 
the plasmid were inserted in the different clones (not shown). 
Thus, the endogenous genes seem to be intact in structure 
Results 
Differential Expression of H-2K  b Molecules in High and Low 
Metastatic  3LL  Clones.  K b  cell  surface  expression  was 
shown to be much higher on low metastatic clones than in 
high metastatic clones of 3LL (15). Low metastatic A9 and 
high metastatic D122 cells were compared for call surface, 
Figure  1.  H-2K  b expression on A9 and D122 cells. (A) Cell surface 
expression was determined  by RIA. (B) RNA and cytoplasmic  K  b heavy 
chain in A9 (lanes I) and D122 (lanes  2) cells. Northern  blot and hybrid- 
ization were  performed  as described  in Materials  and Methods.  Immuno- 
precipitation was performed with antibody  20-8-4 as described (4). 
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Figure 2.  H-2 cell surface expression of 
D122 clones transfected by K  b genes. D122- 
derived genomic K  b clones 2.91 and 4.1 and 
genomic normal K  b clone N.11 were trans- 
fected with PSV2neo  as described in Materials 
and Methods. Isolated single cell clones were 
monitored for K  b and D  b expression by RIA. 
and able to be functionally expressed, even in the original 
D122 cells. 
Differential  Activity of Enhancer  A  in A9 and D122  Cells. 
Since the endogenous K b promoter can be activated in D122 
cells upon transfection of multiple copies of the gene, it seems 
reasonable to assume that  trans-acting  silencer factors exist 
in D122 cells  and these are diluted by excess promoter se- 
quences. To test the activity of enhancer elements of the K b 
gene in A9 and D122 cells,  deletions of the K b promoter 
were fused to the bacterial CAT gene (Fig. 3). These recom- 
binants were transiently cotransfected into A9 and D122 cells 
with pCHl10,  which  express the bacterial 3-galactosidase 
under  the regulation  of the SV40 promoter,  and served as 
an internal control. CAT activity was normalized to ~/-galac- 
tosidase activity for each transfection.  Plasmids containing 
enhancer B, with endpoints at  -117 and  -142, showed low 
and similar activities upon transfection into the two cell types 
(Fig. 3 B). In contrast, the plasmid containing the endpoint 
at  -190 was at least twofold more active in A9 than in D122 
cells, and the plasmid containing the endpoint at  -  365 pro- 
duced a threefold increase in activity between the two cell 
types (Fig. 3 B). These data suggest the participation  of at 
least two enhancer elements in the differential regulation of 
the K b gene in D122 cells, one between  - 142 and  - 190 and 
the other between  -190  and  -365. 
K b Promoter DNA  Binding Proteins in Nuclear Extracts of 
A9 and 19122 Cells.  To examine the nuclear factors binding 
to the K b promoter, nuclear proteins were prepared from A9 
and D122 cells, and examined by electrophoresis  mobility shift 
assay (EMSA), 1 using as a probe the domain  -365 to  +10. 
Three main complexes were detected (Fig.  4, B and C). The 
fastest migrating complex binds to enhancer A only, and is 
competed e~ciently with excess enhancer A (- 205 to - 154), 
1 Abbreviation used in this  paper: EMSA, electrophoresis  mobility shift assay. 
AP2X (-188 to  -169) CILEX (class I regulatory element) 
(-175 to  -154), and CRE (-172 to  -160), (Fig.  4, B and 
C,  lanes  1,  8,  4,  and 3,  respectively), indicating  that  this 
complex binds to the NF-IcB domain,  CRE. This complex 
exists at higher levels in nuclear extracts from D122 cells (Fig. 
4 C) than extracts from A9 cells (Fig. 4 B). The intermediate 
band represents proteins binding to enhancer B only, because 
this protein-DNA  complex is competed with an oligomer 
of enhancer B (- 123 to  -  58) (Fig.  4, B and C, lane 2) and 
is similarly expressed in both cell lines. The slowest migrating 
complex seems to be able to bind both enhancers as it is com- 
peted with oligomers comprising either enhancer A or B (Fig. 
4, B and C, lanes 1 and 2). This complex is also slightly more 
abundant  in D122 extracts. 
To further analyze protein binding to subdomains of the 
promoter, analysis was repeated with enhancer A as a probe. 
Six complexes were identified by EMSA (Fig.  4, E  and F). 
Complexes A1  to A5 but not A6 were more abundant  in 
D122 extracts (compare Fig. 4 E, lane I, to F, lane 8). Com- 
petition analysis indicated that A3 and A4 bind to the NF-~cB 
binding domain and are competed by the minimal 13-bp CRE 
(Fig.  4 E,  lane 5,  and F, lane 4); moreover, when CRE is 
used as a probe, it binds only complexes A3 and A4 (Fig. 
4 F, lane 8, and F, lane 1).  Complexes A1, A2, and A6 are 
bound at the domain partially overlapping CRE and AP2, 
since they are competed by CREX (Fig.  4 E,  lane 2,  and 
F, lane 7), by AP2X (Fig.  4 E, lane 4, and F, lane 5), and 
to some extent with CILE (Fig. 4 E, lane 5, and F, lane 4). 
A5 binds at the AP1A domain and is competed mainly by 
APIAX (Fig.  4 E,  lane 3,  and F, lane 6) and AP1A (Fig. 
4 E, lane 6, and F, lane 3). Analysis of protein binding  to 
enhancer B (-123 to  -58) reveals similar binding proteins 
in extracts of both clones (Fig. 4 D, lanes 2 and 3). The slowest 
migrating proteins are competed by the AP1B domain (Fig. 
4 D, lanes 5 and 6). Nuclear extracts from HeLa cells were 
used as controls (Fig.  4 D,  lanes  I  and 4).  Since the same 
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Figure  3.  Activity  of  K b  pro- 
moter-CAT  constructs in A9 and 
D122 cells. (.4) Schematic represen- 
tation of the K s promoter and the 
various deletion constructs used in 
the CAT assay.  (B) A9 and D122 
cells were transiently transfected by 
the  various  CAT  constructs,  and 
pCHl10 was cotransfected as a con- 
trol gene. 40 h later, extracts were 
prepared  and  CAT  and  /3-galac- 
tosidase activity were monitored as 
described. A 20-h kinetics was per- 
formed from all samples, p38-CAT 
construct gene gave no CAT activity 
in the two cell lines (not shown). 
This experiment is one of six ex- 
periments that gave equal data. 
quantities and batches of nuclear extracts were used for binding 
of the different probes, these data indicate that a number of 
enhancer A binding proteins are more abundant in D122 cells 
than in A9 cells. Analysis of nuclear extracts with CRE as 
a probe showed that levels of complex A3 and A4 (NF-KB 
and KBF1) are similar in A9 cells while D122 cells higher 
levels of A4 than A3 are detected (Fig. 4 G). 
Characterization of Proteins Bound to ~cB Motif in the H-2K  b 
Promoter.  The NF-KB motif in the H-2K  b promoter was 
shown to bind NF-KB (pS0-p65 heterodimer), KBF1 (p50- 
pS0 homodimer), and other related and nonrelated factors. 
To test whether complexes A3 and A4 comprise one of the 
known factors, we used anti-KBFl-specific  antibodies nos. 
2 and 3, which are specific for the p50 homodimer (44). Fig. 
5 A shows that incubation of nudear extracts with antibody 
no. 3 and to a lesser extent no. 2 shifted the pS0 dimer-DNA 
complex to a slower mobility antibody-KBF1-DNA corn- 
plex, and diminated band A4 in EMSA (Fig. 5 A, lanes 3, 
4, 7, and 8). An unrelated antibody did not change the mo- 
bility of the p50 homodimers (Fig. 5 A, lanes 2 and 6). Again 
the differential quantitative levels of KBF-DNA binding ac- 
tivity are obvious between the two call types. Further sup- 
port for the A4 complex containing a p50 homodimer  is shown 
in Fig. 5 B.  Recombinant shortened p50,  which migrates 
slightly faster than pS0 from D122 ceils, reacted similarly with 
the no. 3 antibody to the cellular pS0 homodimer (Fig. 5 
B,  compare lanes 5 and 4 to 2  and 1).  Complex A4 was 
unaffected by addition of human recombinant MAD-3 (Fig. 
5 B, lane 6), an IKB protein cloned from human macrophages 
(66). This indicates the absence of p65 or c-Re1 from the A4 
complex. 
Recombinant p65 (Fig. 5 B, lane 3) could only weakly 
bind to the class I KB motif. Incubation of D122 nuclear ex- 
tracts with recombinant MAD-3 eliminated complex A3 (Fig. 
1655  Plaksin et al. Figure  4.  K b promoter activity in nuclear extracts of A9 and D122.  (A) Schematic representation 
of enhancer  A, enhancer  B, and various fragments used as probes or as competitors. (/3 and C) A 3zp. 
labeled HindllI-Xba fragment of puc-365-CAT, encompassing  the region from -365 to + 10, was used 
as a probe. Nuclear extracts from A9 cells (B) or D122 cells (C) were incubated in presence or absence 
of competitors: no competitor (lanes 10); enhancer  A (lanes 1); enhancer B (lanes 2); CRE (lanes 3); 
CIKEX (lanes 4); AP1A (lanes 5);  AP1AX (lanes 6); AP2 (lanes 7); AP2X (lanes 8); AP1BX (lanes 
9).  (D) A 32P-labeled enhancer  B was incubated with nuclear extracts of Hela cells (lanes 1 and 4); 
A9 (lanes 2 and 5); D122 (lanes 3 and 6) in presence (lanes 1-3) or absence (lanes 4--6) of APIB compe- 
titors. (E and F). A 32P-labeled  enhancer A probe was incubated with extracts of A9 cells (E) and D122 
cells (F). Control (E, lane 1; F, lane 8); CREX  (E, lane 2; F, lane 7); APlAX (E, lane 3; F, lane 6); AP2X (E, lane 4; F, lane 5); CRE  (E, lane 
5; F, lane 4); AP1A (E, lane 6; F, lane 3);  AP2 (E, lane 7; F, lane 2); 32P-CRE was used as a probe (E, lane 8; F, lane 1). (G) A 32P-labeled CRE 
(KBF1/NF-~B binding site) probe was incubated with extracts of A9 cells (lane 1) and D122 cells (lane 2). The mixtures were analyzed by EMSA. 
5 B, lanes 5 and 6).  Although MAD-3 was shown to bind 
both p65  and c-rel, complex A3 was not  shifted or elimi- 
nated by specific c-rel or v-rel antibodies (not shown), indi- 
cating that this complex represents the NF-xB p50-p65 het- 
erodimer. In conclusion, higher levels of KBF1 are found in 
nuclear extracts of D122 cells as compared with A9 cells. In 
D122 nuclear extracts, KBF1 seems to be in excess over NF- 
KB while in A9 extracts NF-xB is in some excess over KBF1. 
Stable Expression of p50 Suppresses Class I Expression while 
Stable Expression  of  p65 Increases  Class  I Expression.  The data, 
so far, suggested that the ratio and relative amounts of KBF1 
and NF-xB may regulate the expression of H-2K  b in the two 
cell lines.  Northern blot analysis  showed that p105 mlkNA 
levels are lower in A9 than in D122 cells (Fig.  6 A). To test 
whether  increased KBF1 levels  affect K b transcription,  we 
have stably transfected A9 cells with CMV-pS01-s~  (53).  By 
only expressing  the NH2-terminal  502  amino  acids  of the 
KBF1 precursor p105, we could circumvent the negative con- 
trol imposed by the IxB-y contained in the COOH-terminal 
portion of p105. Clones expressing the truncated p105 mRNA 
showed, in addition to a novel shorter mlkNA, elevated levels 
of the p105 mRNA (Fig.  6 B). This is in accordance with 
the observation that  p50 can upregulate its own transcrip- 
tion (67). Thus,  pS0 may act as an inducer of transcription 
in variant  KB sequences as those in the promoter  of p105. 
The same clones, however, show the same p65 mRNA levels 
as parental  A9 cells  (Fig.  6 B), indicating  that  the balance 
between p50 and p65 subunits of NF-xB, rather than absolute 
amounts,  controls  class  I  expression.  Three  clones overex- 
pressing  p50  mRNA  showed  a  threefold  decrease  in  K b- 
specific  mRNA levels  (Fig.  6 B)  and revealed  strongly in- 
creased KBF1 DNA binding  activity in EMSA (Fig.  6 C). 
These cells also showed a two- to threefold decreased cell sur- 
face expression of the H-2K  b antigen  (Fig.  6 D, left). Since 
the H-2D  b promoter also contains an NF-KB site, we tested 
whether A9-p50 transfectants are downregulated in H-2D  b 
expression;  a 20-40%  decrease was observed for the three 
(Fig. 6 D, right). To test whether overexpression of p65 might 
1656  KBF1  Acts as a Repressor of H-2K  b Gene Expression Figure 5.  Characterization of xB domain binding proteins. (A) A 
modified  CRE probe  (- 172 to - 148) was incubated  with nuclear extracts 
of A9 (lanes I-4) and D122 (lanes 5-8) in the presence of: no antibody 
(lanes 1 and 5); anti-H-2D  b (lanes 2 and 6); anti-p50 (c,2) (lanes 3 and 
7); anti-pS0 (~3) (lanes  4 and 8). (B) CR.E probe  was incubated with nu- 
clear extracts from D122 cells (lanes 2, 5, and 6) with recombinant p65 
(lane 3); recombinant  p50 (lanes  4) recombinant p50 and c~3 antibody  (lane 
1); nuclear extract and oe3 antibody  (lane  2); and nuclear extract and recom- 
binant IxB (MAD-3) (lane 6). The mixtures were analyzed by EMSA. 
upregulate class I expression of D122 cells, cells were stably 
transfected by CMV-p65.  Fig.  7 A  shows that elevation of 
p65 mRNA levels resulted in increased NF-xB binding ac- 
tivity in EMSA, and in almost complete disappearance of KBF1 
from nuclear extracts of the transfectants  (Fig. 7 B). The trans- 
fectants showed upregulation of K b mRNA (Fig.  7 A) and, 
in accordance,  a 2.5-4-fold elevation in cell surface K b ex- 
pression  (Fig.  7  C,  left). D b cell  surface  expression  was 
elevated approximately twofold (Fig.  7 C,  right). Transfec- 
tion  with  control plasmids  of both A9 and D122 did not 
change K b or D b cell surface expression (not shown). Thus, 
changing  the balance between NF-xB and KBF1 modulates 
transcriptional  activity of the K b promoter.  Elevated NF-xB 
complex  is  correlated  with  activation  of the  genes  while 
elevated KBF1 is correlated with suppression of transcription. 
Discussion 
The downregulation  of MHC class  I gene expression in 
malignant  cells has been shown to be an important  mecha- 
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nism for tumor escape from immune surveillance. In this study 
the molecular basis underlying class I deficiency was inves- 
tigated by comparing a high K b expresser clone to a low ex- 
presser K b done. We have first demonstrated that the endog- 
enous H-2K  b gene is structurally intact and can be expressed 
in the parental  D122 cells similarly to a normal genomic done, 
provided multiple  copies of the gene are  inserted  (Fig.  2). 
A similar conclusion was reached in some other tumor systems. 
For example,  the  IC9  clone of the T10 sarcoma  (H-2  b  x 
H-2  k) does not express K b, K k,  and D k antigens,  however, 
the cloned K b gene from these cells  could be expressed in 
Ltk-  cells and also in the original IC9 cell line from which 
it  was  derived  (68).  Similarly,  the  K b gene  isolated  from 
nonexpresser cells, embryonal carcinoma PCC4-aza-RI, was 
functionally expressed when  transfected into  differentiated 
cells  (69). 
We have further  shown that  suppression of the K b gene 
is at the transcriptional level; low RNA levels correlated with 
the low amount of H-2K  b protein in the cytosol and on the 
cell surface of nonexpressor cells (Fig.  1). CAT assays, using 
various deletions mutants of the K b promoter region,  indi- 
cated that the domain downstream to nucleotides  -142, which 
encompasses enhancer B (containing TATA and CAAT boxes), 
is similarly activated in expresser and in nonexpresser cells 
(Fig. 3). Moreover, nuclear extracts of the two cell lines re- 
vealed similar factors binding to enhancer B at similar con- 
centrations (Fig. 4, B-D). This region, however, shows very 
low activity in A9 and D122 cells.  Similar results were ob- 
tained with constructs containing enhancer B alone in BALB/c 
3T3 cells  and in Ltk-  cells  (25,  52).  CAT constructs con- 
taining enhancers A and B show differential activities in A9 
and D122 cells; a twofold activation is observed in the p190 
CAT that contains the NF-xB binding motif, and a threefold 
activation is observed in the activity of the p365 CAT con- 
struct between the two clones (Fig.  3). The active element 
upstream  of the NF-xB is probably a CREB/ATF/API-like 
binding motif between  -  210 and  -  188.  Purified AP1, cy- 
clic adenosine  monophosphate-inducible transcription factors, 
as well as a member of the nuclear hormone receptor super- 
family, H-2RIIBP, were shown to bind this motif (24, 36, 
70).  We have shown before that  A9 cells  expressed higher 
levels of c-J~s and c-jun than D122 cells and that stable trans- 
fectants of either c-Jos alone or c-J~s +  cjun expression vectors 
increased H-2 expression (71, 72). Transient transfections of 
CAT constructs into c-Jos +  c-jun  D122 over expressers showed 
high activation of the p365 and low activation of the p190 
constructs, indicating also participation  of an API complex 
in upregulation of class I in these cells (Yamit-Hezi, A., D. 
Plaksin, and L. Eisenbach, manuscript  submitted for publi- 
cation). 
Gel shift analysis indicated that some enhancer A binding 
proteins were more abundant in nuclear extracts from D122 
as compared with nuclear extracts from A9 cells (Fig.  4, E 
and F). Most prominent were complexes A3 and A4, which 
bind specifically  to minimal NF-KB domain  -172 to  -160 
(Fig. 4 E, lane 8, and F, lane 1). By the use of specific anti- 
p50 antibodies, which react only with the p50 homodimer 
KBF1, and recombinant IxB (MAD-3), which binds to the Figure 6.  Effect  of pS0 transfection on K  b expres- 
sion in A9 ceUs.(A)  Endogenous  mKNA levels  of p50 
precursor (p105), in D122 (lane 1) and A9 (hne 2) cells. 
~-actin was used as control for equal amounts of  RNA. 
(B) mRNA levels of p65, p50, p105, K  b, and/~-actin 
of A9 (lane I) and A9-p50 transfectant.  (lane 2) (C) 
A 32p CRE probe was incubated with nuclear extracts 
of A9 (lane 1) and A9-p50 transfectants (lanes 2-4). 
The mixtures  were analyzed by EMSA. (/9) H-2K  b 
and H-2D  b cell surface expression of A9 and Ag-p50 
transfectants: H-2K  b (/eft) and H-2Db (right). Cell sur- 
rices were analyzed by KIA as described in Materials 
and Methods. 
p65 subunit and inhibits binding of NF-KB complex to the 
DNA, we found that complex A3 is NF-KB and complex 
A4 represents KBF1 (Fig. 5).  c-rel  and v-rel antibodies did 
not react with any of the complexes, indicating that p65 and 
p50 are probably the only subunits in A3 and A4 complexes. 
The fact that both NF-KB and KBFI activities are increased 
in D122 cells is in apparent discrepancy with a number of 
studies that showed a correlation between class I expression 
and activity of both KBF1 and NF-KB (73, 74). However, 
recently it was demonstrated that the presence of NF-KB but 
not KBF1 seems necessary for class I expression in a variety 
of human tumor cell lines (75), suggesting that it is the bal- 
ance between NF-KB and KBF1 binding that might be the 
determinant for expression of K  b in  3LL  clones.  In  this 
study, we therefore transfected K  b expresser A9 cells with 
a p50 expression vector, and low expresser (D122) cells with 
a p65 expression vector. Elevated K  b mRNA and cell sur- 
face protein in D122-p65 transfectants correlated exclusively 
with binding of NF-KB to the A enhancer motif (Fig. 7). 
On the other hand, increased KBF1 binding in A9-p50 trans- 
fectants correlated with decreased K  b mRNA and cell sur- 
face expression (Fig. 6). 
Controversial results were obtained in various studies as 
to the role of  KBF1 in activation of KB-controlled  promoters. 
KBF1 was implicated in the constitutive basal expression of 
the MHC class I (36) and TNF-c~ gene in murine macro- 
phages (76). Recombinant p50 and p65 subunits of NF-KB 
were shown to independently activate transcription in vitro 
from various KB motifs (56, 57). In contrast,  transient coex- 
pression of  p50 with KB-dependent  reporter constructs in tran- 
sient CAT assays indicated that (p50)2 suppresses the trans- 
activation by NF-~cB in monkey COS and mouse L cells (53). 
Similarly, transient  cotransfection  of excess p50 with low 
amounts of p65 expression vectors decreased expression of 
HIV-gB CAT reporter (77). In nontransformed CD4 + T 
lymphocytes, antigenic stimulation, which upregulates IL-2 
gene expression, decreased the levels of KBF1 and increased 
the levels of NF-~B, indicating a physiological function for 
(p50)2 homodimers in suppression of IL-2 expression (55). 
Another study using cell hybrids containing only K_BF1 but 
not active NF-~cB did not activate the IL-2 receptor KB en- 
hancer (78). Similarly, coexpression of (p50)a with a reporter 
plasmid containing HIV-1 r,B motif caused no activation of 
the reporter gene (54). Unlike KBF1, homodimers of p65 
clearly have  trans-activating function although it is not clear 
whether p65 homodimers actually exist in intact cells (53). 
Moreover, (p65)2 homodimers have a reduced affinity for all 
KB motifs tested so far (56). Also, a heterodimer of p50 and 
1658  KBF1 Acts as a Repressor of H-2K  b Gene Expression Figure 7.  Effect  of  p65 transfec- 
tion  on  K  b  expression  in  D122 
cells. (A) mRNA levels  of  p65 (to/,); 
K  b (middle); and B-actin (bottom) of 
D122 (lane I) and D122-p65 trans- 
fectants (lanes 2 and 3). (B) A 32p 
CRE probe was incubated with nu- 
clear extracts of D122 (lane 4) and 
D122-p65 transfectants (lanes 1-3). 
The  mixtures  were  analyzed  by 
EMSA. (C) H-2K  b and H-2D  b cell 
surface  expression  of  D122  and 
D122-p65  transfectants:  H-2K  b 
(left) and H-2D  b (right).  Cell sur- 
faces were analyzed by RIA as de- 
scribed in Materials and Methods. 
p65 (NF-KB) showed activating properties both in vitro and 
in vivo (53, 55-57).  It is surprising  however that the low 
expresser clone D122 shows higher levels of NF-KB than the 
high expresser clone A9. A possible explanation may reside 
in the relative affinities of NF-KB and KBF1 in the H-2 gB 
motif. Recently it was shown that KBF1 has a higher affinity 
to the H-2-KB motif than NF-IcB, with Kd values of 6.2 and 
10.9 pM, respectively (56). KBF1, which is highly expressed 
in D122 nuclear extracts,  might therefore prevent binding 
oftrans-activating  NF-~B by occupying ~B binding sites. Trans- 
fection of multiple copies of the K  b promoter may dilute the 
excess of KBF1 and  enable  activation  of K b  expression. 
Elevating the concentration of  NFqcB by overexpressing p65 
has a similar effect on activation  of K  b expression. 
In conclusion,  this study demonstrates  that KBF1 might 
have an inhibitory function on class I promoters containing 
gB motif in vivo, and that the balance between the p50 and 
p65  subunits  of NF-KB is crucial for class I expression. 
Although the K  b gene is barely expressed in D122 cells, 
the H-2D  b gene is expressed at detectable levels. In A9 calls 
the D b gene is expressed at approximately threefold the den- 
sity than it is on D122 cells. How can these allele-specific 
differences between K  b and D b expression in D122 cells be 
explained? Comparison of promoter sequences in the two 
alleles showed that enhancer A is highly homologous between 
the two promoters. Indeed, transcription by p65 devated also 
D b expression and transfection by pS0 suppressed partially 
D b expression. Enhancer B on the other hand shows 14/66 
differences in nucleotide sequences (25, 79). It is conceivable 
that different  factors  may  bind to enhancer B and affect  differen- 
tially basal level expression of class I alldes. Such differences 
were observed in EMSA using enhancer B sequences of K  b 
and D b and nuclear extracts  from A9 and D122 cells (R. 
Goodenow, personal communication). Allde-specific down- 
regulation of class I alleles was reported in several human 
tumors (80-84).  It will be of interest to further investigate 
mechanisms involved in allde-specific regulation of class I 
genes. 
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